Abcam, ab259141, Human SLCO4A1 knockout HeLa cell lysate

Size: 1Kit
SLCO4A1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2 and Insertion of the selection cassette in exon 2.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2 and Insertion of the selection cassette in exon 2.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SLCO4A1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SLCO4A1 also known as solute carrier organic anion transporter family member 4A1 functions as a transporter protein involved in the translocation of organic anions across cell membranes. With an approximate mass of 80 kDa SLCO4A1 facilitates the movement of large often negatively charged molecules playing a part in cellular uptake processes. Its expression is noticeable in several tissues including the liver kidney and heart indicating its role in the systemic circulation and excretion of various substrates.
Biological function summary
SLCO4A1 is engaged in the transport of hormones drugs and metabolites across cellular compartments. It belongs to the larger family of solute carriers and does not necessarily form part of a multi-protein complex operating as a standalone transporter. Its activity influences the cellular internalization of various biologically active compounds marking its importance in balancing intracellular and extracellular concentrations.
Pathways
SLCO4A1 integration is seen in critical pathways like drug metabolism and steroid hormone metabolism. In the context of drug metabolism it works alongside cytochrome P450 enzymes to ensure the proper processing and elimination of pharmaceutical compounds. In steroid hormone metabolism it interacts with proteins such as SHBG (sex hormone-binding globulin) to modulate hormone bioavailability influencing physiological responses.
SLCO4A1 shows connections to conditions such as cholestasis and certain drug-induced toxicities. In cholestasis the impaired function of SLCO4A1 can disrupt bile acid transport aggravating liver function issues. Furthermore its interplay with hepatic transporters like SLCO1B1 can affect drug pharmacokinetics raising susceptibility to drug-induced liver injury. Understanding these interactions aids in assessing risk factors associated with SLCO4A1 dysfunction in disease states.